What CanSinoBIO does

CanSino Biologics Inc. (CanSinoBIO) is a Chinese biopharmaceutical company founded in 2009 and dual-listed on the Shanghai STAR Market (688185.SH) and the Hong Kong Stock Exchange (06185.HK), headquartered in Tianjin with additional operations in Beijing, Shanghai, Hong Kong, Toronto, and Singapore. The company develops, manufactures, and commercializes vaccines for human use, with six launched products built on five proprietary technology platforms: adenovirus Type 5 viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery. Marketed products include Convidecia and Convidecia Air (COVID-19 vaccines, including the world's first inhaled adenoviral vector COVID-19 vaccine), Menhycia (Asia's first MCV4 meningococcal conjugate vaccine), Menphecia (bivalent meningococcal conjugate vaccine), iPneucia (China's first dual-carrier PCV13 pneumococcal vaccine), and Tripedia (China's first three-component DTcP combination vaccine for infants). The pipeline includes PCV24, Td5cp (adolescent/adult pertussis), an inhaled tuberculosis vaccine, a recombinant polio vaccine backed by the Bill & Melinda Gates Foundation, and an mRNA multivalent influenza vaccine.

CanSinoBIO generates revenue through vaccine product sales across China's dual-track vaccine market — large-volume, price-regulated procurement under the National Immunization Program alongside a growing private-pay segment for adult boosters and novel platforms. The company employs a unique Direct Sales and Sales Agency Model with commercial access to 31 provinces in China, supported by a Commercial Operation Center (COC). Internationally, the company pursues regulatory approvals and localization partnerships in 15+ countries across Southeast Asia, the Middle East, North Africa, Latin America, and Eastern Europe. Full-year 2025 revenue reached RMB 1.068 billion (~USD 148M), representing 26.18% year-on-year growth, with net profit of RMB 27.87 million marking a return to profitability after a 2024 net loss. The customer base spans Chinese national immunization programs, international governments (Indonesia, Morocco), and regional pharmaceutical partners (Etana, Solution Group, SPIMACO).

Name

CanSinoBIO

Legal name

CanSino Biologics Inc.

Website

https://cansinotech.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

CanSinoBIO is a Chinese biopharmaceutical company developing, manufacturing, and commercializing innovative vaccines across five proprietary technology platforms, serving government immunization programs and private-pay markets in China and 15+ international markets with six launched products including MCV4, PCV13, DTcP, and COVID-19 vaccines.

Ownership category

akta.pro rank

Product category

Human Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

Keywords

• Vaccine development
• Infectious disease prevention
• Biopharmaceutical manufacturing
• Conjugate vaccines
• Viral vector vaccines

Headquarters

HQ city

Tianjin

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Infrastructure, Personnel, Marketing or Sales, Operations

Revenue model

1. Vaccine Product Sales: CanSinoBIO generates revenue primarily through sales of its launched vaccine products including Convidecia, Convidecia Air, Menhycia, Menphecia, iPneucia, and Tripedia. The company reported full-year 2025 revenue of RMB 1.068 billion representing 26.18% year-on-year growth.
2. National Immunization Program (NIP) Public Procurement: China's vaccine market operates under a dual-track system with large-volume, price-regulated public procurement for the National Immunization Program alongside a growing private-pay market for adult boosters and novel platforms.
3. Private Pay Market: Growing private-pay market for adult boosters and novel vaccine platforms. Private market sales for innovative vaccines not included in the national immunization program.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

CanSinoBIO is an industry-leading biopharmaceutical company that researches, develops, manufactures, and commercializes innovative vaccines for human use targeting infectious diseases. The company markets six products spanning meningococcal (Menhycia, Menphecia), pneumococcal (iPneucia), pertussis-based DTcP (Tripieza), and COVID-19 (Convidecia, Convidecia Air) vaccines, built on five proprietary technology platforms including adenovirus-based viral vector, synthetic biotechnology, protein structure design and VLP assembly, mRNA/LNP, and formulation/drug delivery.

Product overview

CanSinoBIO is an industry-leading biopharmaceutical company offering a diversified portfolio of innovative vaccines for human use. The company has launched 6 marketed products built on 5 technology platforms (adenovirus-based viral vector, synthetic biotechnology, protein structure design/VLP assembly, mRNA/LNP, and formulation/delivery). The portfolio includes: Tripieza (first-in-class DTcP vaccine for infants), Menhycia (Asia's first MCV4 meningococcal vaccine), iPneucia (first dual-carrier PCV13), Menphecia (bivalent meningococcal vaccine), Convidecia (adenovirus vector COVID-19 vaccine, WHO EUL), and Convidecia Air (world's first inhaled COVID-19 vaccine). The pipeline includes PCV24, Td5cp, inhaled tuberculosis vaccine, recombinant polio vaccine, and mRNA influenza vaccine.

Differentiator

Problem solved

Functional benefit

Brands

• Tripecia®: Three-Component DTcP Vaccine (adsorbed diphtheria, tetanus and pertussis (acellular, three component) combined vaccine) — first approved DTcP vaccine in China for infants.
• Menhycia®
• Menphecia®
• iPneucia®
• Convidecia®
• Convidecia Air®

Products and services

• Convidecia Recombinant COVID-19 Vaccine using Adenovirus Type 5 Vector. Single-dose vaccine providing humoral and cellular immunity. WHO Emergency Use Listed and conditionally approved by China NMPA.
• Convidecia Air World's first aerosolized recombinant viral vector COVID-19 vaccine for inhalation. Needle-free, providing triple comprehensive protection including mucosal immunity without intramuscular injection, leveraging the same adenovirus vector technological platform as Convidecia.
• Menhycia Group ACYW135 Meningococcal Conjugate Vaccine using CRM197 carrier protein. China's first-in-class and first NDA approved MCV4 vaccine covering serogroups A, C, Y, and W135. Indicated for infants and children aged 3 months to 6 years.
• Menphecia Group A and Group C Meningococcal Conjugate Vaccine using CRM197 carrier protein. China best-in-class bivalent meningococcal vaccine competing with domestic MCV2 products commercialized by well-known manufacturers in China.
• iPneucia 13-Valent pneumococcal polysaccharide conjugate vaccine (PCV13*i) using dual-carrier conjugation technology with CRM197 and tetanus toxoid (TT). China's first pneumococcal conjugate vaccine with dual-carrier technology, approved for children aged 6 weeks to 5 years, exhibiting enhanced immunogenicity against serotypes 19F, 19A, 7F, and 3.
• Tripeza Three-Component DTcP Vaccine (adsorbed diphtheria, tetanus and pertussis acellular vaccine) for infants. Contains pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) antigens. First-in-class approved DTcP vaccine in China.

Quantifiable outcome

• 14-day protection efficacy: 68.83% effective in preventing all symptomatic COVID-19 disease and 95.47% effective in preventing severe COVID-19 disease
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core, major and supporting.

• Beijing Institute of BiotechnologycoreStrategic or Co-development PartnerCo-developed Convidecia recombinant COVID-19 vaccine with the Beijing Institute of Biotechnology, Academy of Military Medical Sciences. Previously jointly developed the recombinant Ebola vaccine approved in China in 2017.
• Etana (Indonesia)majorStrategic or Co-development PartnerTripartite cooperation agreement on inhaled tuberculosis vaccine development. CanSinoBIO and Indonesian Biopharmaceutical Company Etana collaborating on TB vaccine development and commercialization in Indonesia.
• Solution Group Berhad (Malaysia)majorStrategic or Co-development PartnerSigned share subscription agreement for vaccine fill-and-finish facilities development. Collaboration includes mRNA multivalent influenza vaccine development with local institutions in Malaysia.
• SPIMACO (Saudi Arabia)majorStrategic or Co-development PartnerSigned cooperation framework agreement on innovative vaccine with Saudi Arabia's pharmaceutical manufacturing company. Exploring joint R&D and localized production opportunities in the Middle East.
• National Research Council CanadasupportingTechnology or IntegrationInternational R&D partnership enhancing innovative capabilities through collaboration with prominent research organizations worldwide.
• BIRD-CsupportingTechnology or IntegrationInternational R&D partnership for vaccine development and technology advancement.
• VaccitechsupportingTechnology or IntegrationR&D collaboration partnership with Vaccitech for vaccine technology development.
• Peking UniversitysupportingStrategic or Co-development PartnerJoint training programs with Peking University to cultivate emerging young professionals equipped for competitive environment in biotechnology.
• Nankai UniversitysupportingStrategic or Co-development PartnerJoint training programs with Nankai University for talent development in biotechnology and vaccine research.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Moderna: mRNA platform vaccine leader with COVID, RSV, influenza, and emerging pipeline products. Comparable through CanSinoBIO's mRNA/LNP platform ambitions and overlap in respiratory and combination vaccine development.
• GSK Vaccines: Global top-tier vaccine developer with Menveo/MenQuadfi (meningococcal), Bexsero/Shingrix portfolios, and large pediatric NIP presence. Comparable as an incumbent CanSinoBIO competes against in emerging-market MCV4 tenders and combination-vaccine development.
• China National Biotec Group (Sinopharm): State-owned largest Chinese vaccine manufacturer offering a broad NIP portfolio (polio, measles, hepatitis, influenza, COVID). Direct competitor for NIP tenders and emerging-market supply contracts that CanSinoBIO is targeting.
• Sanofi Pasteur: Global vaccine franchise spanning influenza, meningococcal (MenQuadfi), pediatric combinations (Hexaxim/Vaxelis), and PCV (nirsevimab-adjacent programs). Comparable as a broad incumbent competing in NIP and private-pay markets CanSinoBIO targets.

Emerging players

• Bharat Biotech: India-based emerging-market vaccine specialist with broad portfolio including rotavirus (ROTAVAC), typhoid conjugate, and COVID vaccines. Comparable as an emerging-market champion targeting infectious disease tenders and WHO PQ, with similar platform diversification ambitions.
• Serum Institute of India: Largest vaccine manufacturer by doses globally, supplying low-cost NIP vaccines across emerging markets. Comparable in scale-driven emerging-market export model and WHO PQ-eligible pneumococcal, meningococcal, and polio products that compete with CanSinoBIO.
• Novavax: US-listed protein subunit / VLP platform vaccine developer (Nuvaxovid COVID vaccine, R21/Matrix-M malaria). Comparable in platform-based approach, including VLP/Matrix-adjuvant technology, though at a different stage of commercial maturity.

Direct peers

• Sinovac Biotech: Beijing-based vaccine developer with a comparable portfolio spanning COVID-19 (CoronaVac), influenza, enterovirus, and hepatitis vaccines. Closest analog to CanSinoBIO in terms of Chinese origin, WHO-listed COVID vaccine, and emerging-market export focus.
• Walvax Biotechnology: Kunming-headquartered Chinese vaccine maker with meningococcal, pneumococcal, HPV, and influenza products. Direct competitor in bivalent meningococcal and PCV13 markets where CanSinoBIO's Menphecia and iPneucia compete.
• Zhifei Biological Products: Chinese-listed vaccine major distributing Merck's PCV13/PCV15 and operating domestic ACYW135 meningococcal franchise. Competes head-to-head with CanSinoBIO's Menhycia and iPneucia on NIP and private-pay channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanSinoBIO